

WHAT IS CLAIMED IS:

1. A medical device comprising:
an implantable structure;
5 a basecoat matrix, including a combination of rapamycin and cladribine, in therapeutic dosages, incorporated in a first polymeric material, the basecoat matrix being affixed to the surface of the implantable medical device; and
a topcoat, including a second polymeric material, affixed to the
10 basecoat matrix for controlling the elution rate of the rapamycin and cladribine.
2. The medical device according to claim 1, wherein the implantable structure comprises a stent.
- 15 3. The medical device according to claim 1, wherein the implantable structure comprises a stent-graft.
4. The medical device according to claim 1, wherein the implantable
20 structure comprises an anastomosis device.
5. The medical device according to claim 1, wherein the second polymeric material is incompatible with the first polymeric material, thereby creating both a physical and chemical barrier to the elution of
25 the rapamycin and cladribine.
6. The medical device according to claim 5, wherein the first polymeric material comprises a fluoropolymer.
- 30 7. The medical device according to claim 5, wherein the second polymeric material comprises an acrylic.

8. A medical device comprising:
an implantable structure; and
a combination of rapamycin and cladribine, in therapeutic
dosages, releasably affixed to the implantable structure for the
treatment of restenosis following vascular injury.
9. The medical device according to claim 8, wherein the implantable
structure comprises a stent.
10. The medical device according to claim 8, wherein the implantable
structure comprises a stent-graft.
11. The medical device according to claim 8, wherein the implantable
structure comprises an anastomosis device
12. The medical device according to claim 8, further comprising a
polymeric coating, the combination of rapamycin and cladribine being
incorporated into the polymeric coating.
13. A method for treating restenosis comprising the local
administration of a therapeutic dose of a combination of rapamycin and
cladribine.
14. A method for treating restenosis comprising the administration of
a therapeutic dose of a combination of rapamycin and cladribine.